Pipeline

Program
  • Target analysis &
    Lead design
  • Hit/Lead
    discovery
  • Candidate
    discovery
  • Non-clinical
    studies &
    IND filing
  • Clinical
    studies

Oncology

Cancer stemness blocking agent (PMB212)

Immunology

Novel IBD therapeutics (PMB702)

•(Expandable to other IMID & fibrosis)

New Drug Platform

Bispecific small molecule: BSM

•(The 3rd-Generation
Immuno-oncology therapeutics)

New Drug Platform

Inhibitor-drug conjugates: IDC

•(Anti-cancer drug)